Biosimilars name, notification debates rage on in the US, but costs still 'elephant in the room'
This article was originally published in SRA
Executive Summary
Whatever the ultimate outcome turns out to be for the debates in the US over the naming of biosimilars or prescriber notification of interchangeable products, the medicines are bound to be "among the most deeply analyzed and predictable" drugs to hit the US market, said Dr Emily Shacter, a former Food and Drug Administration official and now an independent consultant with ThinkFDA.